|
Background and Purpose of lung cancer both in men and in women, has become the leading cause of death from cancer. According to statistics, the 2001 worldwide 1.2 million new patients with lung cancer, died of lung cancer in 1 million, 80% of patients with non-small cell lung cancer (non-small cell lung cancer, NSCLC) patients. The treatment of most patients have advanced, part was diagnosed at an early stage, but eventually relapse. Although chemotherapy in patients with early played a certain role, but the purpose of the treatment of non-small cell lung cancer, is still disappointing. Therefore, the study of new therapeutic approach is necessary. Pituitary tumor transforming gene (pituitary tumor-transforming gene, PTTG) Pei equal to the 1997 differences PCR method first isolated from rat pituitary tumor cell line GH4 an oncogene, the study found PTTG can be expressed in a variety of tumor , PTTG protein has multiple functions, it is involved in cell proliferation, differentiation, apoptosis, and signal transduction important mechanism is closely related with tumor development. PTTG can promote the expression of other pro-tumor factor nuclear oncogenes (c-myc), basic fibroblast growth factor (basic fibroblast growth factor, bFGF), bFGF and PTTG most closely to promote tumor angiogenesis is achieved by bFGF. Blood vessel formation is the key step in tumor development and metastatic spread, the incidence of solid tumors, the degree of malignancy, growth and metastasis and prognosis of. , BFGF plays an important role in the regulation of angiogenesis, bFGF in pro-angiogenic effect may be involved in a variety of malignant transformation. Currently, the molecular mechanisms of angiogenesis has become a hot spot within the field of cancer research, targeted therapy for angiogenesis has been some progress in the treatment of non-small cell lung cancer. Therefore, in-depth research PTTG and bFGF occurred role in the development of mechanisms to provide new ideas for the treatment of lung cancer in non-small cell lung cancer. In this study, using immunohistochemical method (SABC) study in non-small cell lung cancer and normal lung tissue PTTG and bFGF expression and correlation, to further explore the expression of PTTG and bFGF in lung cancer, the role in the development and transfer between relationship, predict metastasis and biological treatment to provide a theoretical basis for the clinical diagnosis of lung cancer. Materials and methods to collect the First Affiliated Hospital of Zhengzhou University, thoracic surgery resection from January 2002 to November 2005 and confirmed by pathology of non-small cell lung carcinoma and adjacent normal lung tissue specimens, including 42 males and 19 females. Age 36-81 years old, with a median age of 57 years old, the average age of 57.77 ± 9.83 years; greater than or equal to 60 years of age and 33 cases, 28 cases less than 60 years old. Histological classification: 36 cases of squamous cell carcinoma, adenocarcinoma, 25 cases; well differentiated in 10 cases, in the differentiation of the 28 cases, poorly differentiated 23 cases. 37 cases without lymph node metastasis in the 61 cases, 24 cases with lymph node metastasis; TNM staging: 7 cases of Ⅰ 14 cases, Ⅱ, Ⅲ 28 cases, Ⅳ 12 cases, all patients without radiotherapy before surgery chemotherapy and other treatments to adjacent normal lung tissue as a control. All specimens were in 10% formalin solution fixed, paraffin-embedded, made of slices of 4 μm, respectively hematoxylin - eosin (HE) staining and PTTG and bFGF immunohistochemical staining. Results are analyzed using statistical software SPSS13.0 analysis of the expression of PTTG protein and bFGF protein positive rate χ ~ 2 test and Fisher's exact test was used to compare spearman correlation analysis, correlation analysis, with a = 0.05 as the level of inspection. Results 1. The PTTG tissues: NSCLC of PTTG positive expression rate was 68.85%, significantly higher than the normal lung tissue PTTG expression (15.00%) (P <0.05); positive expression rate of expression of PTTG in adenocarcinoma (84.00% ) than in squamous cell carcinoma (58.33%); expression of PTTG in high school moderately and poorly differentiated non-small cell lung cancer positive expression rate of 57.89%, 86.95%, and the difference was statistically significant (P <0.05); expression of PTTG in lymph node metastasis The positive expression rate of lung cancer (81.08%) was significantly higher than those without lymph node metastasis in lung cancer tissues (50.00%); relationship of PTTG expression with clinical stage III-IV patients with the PTTG positive expression rate (82.50%) is higher than Ⅰ Ⅱ (42.86%), the difference was statistically significant (P <0.05). That PTTG expression in NSCLC tissues with different pathological type, degree of differentiation of the tumor, lymph node metastasis and TNM staging is closely related; expression of PTTG expression with age, regardless of gender (P> 0.05). 2. bFGF in tissues: NSCLC tissue of bFGF positive expression rate was 73.77%, significantly higher than that in normal lung tissue in bFGF expression (10.00%) (P <0.05); squamous cell carcinoma, adenocarcinoma of bFGF positive expression rates were 72.22%, 76.00%, no statistically significant difference between the two; bFGF in moderately differentiated and poorly differentiated non-small cell lung cancer positive expression rate of 63.16%, 91.30%, the difference was statistically significant ( P <0.05); bFGF in lymph node metastasis of lung cancer, the positive expression rate (83.78%) was significantly higher than those without lymph node metastasis in lung cancer tissues (58.33%); of bFGF in expression with clinical stage III-IV patients bFGF The positive expression rate (85.00%) in Ⅰ Ⅱ (52.38%), the difference was statistically significant (P <0.05). The results showed that bFGF expression in NSCLC tissues and tumor differentiation, lymph node metastasis and TNM staging is closely related; of bFGF expression with age, gender, pathological regardless of the type (P> 0.05). 3. PTTG protein and bFGF protein expression in NSCLC tissues: In 61 patients with non-small cell lung cancer of PTTG protein with bFGF total positive in 35 cases, negative for a total of nine cases, the expression of both a positive correlation between the (r_s = 0.323, P <0.05) . Conclusion 1. The PTTG expression enhanced in NSCLC tissues was significantly higher than in normal lung tissue, indicating that PTTG involved in NSCLC occurrence. PTTG expression in NSCLC tissues with different pathological type, tumor differentiation, lymph node metastasis and TNM stage, indicating that PTTG involved in the development of NSCLC. PTTG expression is more common in adenocarcinoma, which reveals the the lung adenocarcinoma easy early occurrence of the molecular basis of blood metastasis, and its expression of great significance to the development and prognosis of NSCLC. 2. enhanced expression of bFGF in NSCLC tissues was significantly higher than in normal lung tissue. expression of bFGF with the degree of differentiation of the tumor, lymph node metastasis and TNM staging related; bFGF expression has nothing to do with age, gender, pathological type, show that the expression of bFGF enhanced invasive development with NSCLC and is closely related to angiogenesis, bFGF as evaluation of lung cancer prognostic indicators. 3. PTTG and bFGF protein highly expressed, expression of PTTG and bFGF expression in non-small cell lung cancer were being related, prompt activation bFGF expression PTTG may promote the formation of microvascular a important role in the development of lung cancer, and expression of PTTG gene is expected to become lung new tumor molecular markers new ideas and targets for gene therapy for the treatment of lung cancer.
|